<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075798</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2021/II-01</org_study_id>
    <secondary_id>IRB21.09.02</secondary_id>
    <nct_id>NCT05075798</nct_id>
  </id_info>
  <brief_title>Study of Cerebral MRI Anomalies in Mutated Transthyretin Amyloidosis Patients</brief_title>
  <acronym>TTR-SNC</acronym>
  <official_title>A Comprehensive Retrospective Study of Cerebral MRI Anomalies in Mutated Transthyretin Amyloidosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transthyretin amyloidosis (aTTR) initially described as a rare disease, became the most&#xD;
      serious hereditary polyneuropathy of adult onset and family screening has made it possible to&#xD;
      identify and follow up many asymptomatic patients and carriers of the mutation in the TTR&#xD;
      gene.&#xD;
&#xD;
      Considered as a systemic disease with involvement of target organs (the heart, the eye, the&#xD;
      kidney and peripheral nervous system), it seems to be more complex for neurologists according&#xD;
      to recent publications raising the issue of central nervous system involvement.&#xD;
&#xD;
      Indeed, TTR amyloid deposits seem to be correlated with the duration of the disease. These&#xD;
      deposits can cause cortical damage by different mechanisms: direct TTR toxicity or as a&#xD;
      result of pathology related to cerebral amyloid angiopathy (intraparenchymal or subarachnoid&#xD;
      hematomas, small infarcts, hemosiderin). A small number of mutations in the TTR gene cause a&#xD;
      rare phenotype of systemic amyloidosis, the oculoleptomeningeal form, characterized by&#xD;
      clinical neurological symptoms: progressive dementia, epilepsy, ataxia, spastic paraparesis,&#xD;
      stroke-like episodes.&#xD;
&#xD;
      Hypothesis of the work: the central nervous system involvement is probably underestimated on&#xD;
      the radiological description in patients with TTR mutation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical-radiological characterization</measure>
    <time_frame>Baseline</time_frame>
    <description>Presence of signs of chronic bleeding on brain MRI (Yes/No)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Transthyretin Amyloidosis</condition>
  <arm_group>
    <arm_group_label>group patients</arm_group_label>
    <description>Patients followed at the University Hospital of Nîmes between 2017 and 2021 for a TTR neuropathy with proven mutation, having benefited from a brain MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention,</intervention_name>
    <description>pure observational study</description>
    <arm_group_label>group patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients followed at the University Hospital of Nîmes between 2017 and 2021 for a TTR&#xD;
        neuropathy with proven mutation, having benefited from a brain MRI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients followed at the University Hospital of Nîmes between 2017 and 2021 for a TTR&#xD;
             neuropathy with proven mutation, having benefited from a brain MRI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients without TTR neuropathy with proven mutation, or who did not have a brain MRI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anissa MEGZARI</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nīmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ioana Maria ION</last_name>
    <phone>+33 4 66 68 32 61</phone>
    <email>IOANAMARIA.ION@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa MEGZARI</last_name>
      <phone>+33 4 66 68 67 15</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ikeda SI. [Cerebral amyloid angiopathy with familial transthyretin-derived oculoleptomeningeal amyloidosis]. Brain Nerve. 2013 Jul;65(7):831-42. Review. Japanese.</citation>
    <PMID>23832986</PMID>
  </reference>
  <results_reference>
    <citation>Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. Biomol Concepts. 2014 Mar;5(1):45-54. doi: 10.1515/bmc-2013-0038. Review.</citation>
    <PMID>25372741</PMID>
  </results_reference>
  <results_reference>
    <citation>Maia LF, Magalhães R, Freitas J, Taipa R, Pires MM, Osório H, Dias D, Pessegueiro H, Correia M, Coelho T. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):159-67. doi: 10.1136/jnnp-2014-308107. Epub 2014 Aug 4.</citation>
    <PMID>25091367</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakagawa K, Sheikh SI, Snuderl M, Frosch MP, Greenberg SM. A new Thr49Pro transthyretin gene mutation associated with leptomeningeal amyloidosis. J Neurol Sci. 2008 Sep 15;272(1-2):186-90. doi: 10.1016/j.jns.2008.05.014. Epub 2008 Jun 24.</citation>
    <PMID>18579156</PMID>
  </results_reference>
  <results_reference>
    <citation>Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):124-37. doi: 10.1136/jnnp-2011-301308. Epub 2011 Nov 5. Review.</citation>
    <PMID>22056963</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

